Vivos Therapeutics (VVOS) Accumulated Expenses (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Accumulated Expenses for 8 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 120.58% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (up 120.58% YoY), while the FY2025 annual figure was $6.0 million, up 498.2% from the prior year.
• Accumulated Expenses fell to $1.6 million in Q1 2026 per VVOS's latest filing, from $6.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $6.0 million in Q4 2025 and bottomed at $724000.0 in Q1 2025.
• Historically, Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $1.5 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 53.14% — and 2025, when it soared 498.2%.
• Vivos Therapeutics' Accumulated Expenses stood at $1.4 million in 2022, then increased by 10.31% to $1.5 million in 2023, then sank by 33.18% to $1.0 million in 2024, then jumped by 498.2% to $6.0 million in 2025, then slumped by 73.33% to $1.6 million in 2026.
• Business Quant data shows VVOS's Accumulated Expenses at $1.6 million in Q1 2026, $6.0 million in Q4 2025, and $1.2 million in Q3 2025.